Can Sarepta’s ELEVIDYS redefine Duchenne therapy? Inside the 3-year EMBARK data
Sarepta’s gene therapy ELEVIDYS shows 3-year durability in Duchenne muscular dystrophy. Find out what it means for patients, payers, and global rollout.
Pharma & Biotech
Pharma & Biotech
What does Swissmedic approval of Santhera’s AGAMREE mean for long-term steroid treatment in Duchenne muscular dystrophy?
Swissmedic approves Santhera’s AGAMREE for Duchenne muscular dystrophy. Find out how vamorolone could reshape long-term steroid treatment strategies.